All In Biotech

Drug Trial Radar · NCT06799000

A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)

A Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over a 68-week Treatment Period in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa. (RECHARGE-1)

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 588 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

588

Actual

Start

Jan 31, 2025

Primary completion

May 17, 2027

Study completion Oct 4, 2027

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jan 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to establish the efficacy, safety, and tolerability of remibrutinib (LOU064) Dose A and Dose B compared to placebo in participants with moderate to severe hidradenitis suppurativa (HS).

Conditions

  • Hidradenitis Suppurativa

Interventions

  • Remibrutinib Dose ADrug

    Remibrutinib Dose A (oral)

  • Remibrutinib Dose BDrug

    Remibrutinib Dose B (oral)

  • Placebo 1Drug

    Placebo matching to remibrutinib Dose A (oral)

  • Placebo 2Drug

    Placebo matching to remibrutinib Dose B (oral)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with Hidradenitis Suppurativa clinical response 50 (HiSCR50) at Week 16Time frame: Week 16

Locations

139 sites in 20 countries. Site status is shown where the registry gives one.

  • Medical Dermatology Specialists

    Phoenix, Arizona

  • Johnson Dermatology

    Fort Smith, Arkansas

  • Arkansas Research Trials

    North Little Rock, Arkansas

  • Cheryl Effron MD Inc

    Anaheim, California

  • Physioseq

    Sacramento, California

  • Olive View UCLA Medical Center

    Sylmar, California

  • Clinical Trials Research Institute

    Thousand Oaks, California

  • Howard University College of Medicine

    Washington D.C., District of Columbia

  • Florida Academic Centers Research and Education LLC

    Coral Gables, Florida

  • University of MiamiHealth System

    Miami, Florida

  • Ziaderm Research LLC

    North Miami Beach, Florida

  • Revival Research Institute LLC

    Evans, Georgia

  • Gwinnett Clinical Research Center

    Snellville, Georgia

  • Immunology-Rheumatology Research

    Suwanee, Georgia

  • Illinois Dermatology Institute

    Chicago, Illinois

  • Dawes Fretzin Clinical Rea Group

    Indianapolis, Indiana

  • Equity Medical LLC

    Bowling Green, Kentucky

  • Dermat. and Adv. Aesthetics

    Lake Charles, Louisiana

  • Michigan Center for Rsrch Company

    Clarkston, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • Revival Research Institute

    Troy, Michigan

  • University of Mississippi Med Ctr

    Jackson, Mississippi

  • Care Access Hoboken

    Hoboken, New Jersey

  • Forest Hills Dermatology Group

    New York, New York

  • Icahn School Of Med At Mount Sinai

    New York, New York

  • Skinsearch of Rochester Inc

    Rochester, New York

  • OnSite Clinical Solutions LLC

    Huntersville, North Carolina

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina

  • Unity Clinical Research

    Oklahoma City, Oklahoma

  • Essential Medical Research

    Tulsa, Oklahoma

  • UP Medical Center H System

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina MUSC

    Charleston, South Carolina

  • Advanced Research Experts

    Nashville, Tennessee

  • Bellaire Dermatology Associates

    Bellaire, Texas

  • RFSA Dermatology

    San Antonio, Texas

  • Virginia Clinical Research

    Norfolk, Virginia

  • Novartis Investigative Site

    CABA, Argentina

  • Novartis Investigative Site

    Caba, Buenos Aires, Argentina

  • Novartis Investigative Site

    CABA, Buenos Aires, Argentina

  • Novartis Investigative Site

    Rosario, Santa Fe Province, Argentina

Showing 40 of 139 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.